Biorestorative Therapies, Inc. current report, 19 October 2016

Full document

Business Context and Reporting Period

This Form 8-K filing by BioRestorative Therapies, Inc. reports on the Annual Meeting of Stockholders held on October 19, 2016. The company is incorporated in Delaware and maintains its principal executive offices in Melville, New York.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

Stockholders voted on four primary matters at the Annual Meeting:

  • Election of Class II Directors: Nominees John M. Desmarais and Paul Jude Tonna were elected. Both received over 1.9 million votes "For" with minimal votes withheld.
  • Executive Compensation: The proposal was approved with 1,878,555 votes "For" versus 3,325 "Against."
  • Equity Plan Amendment: Stockholders approved an amendment to the 2010 Equity Participation Plan, increasing the authorized share count from 2,250,000 to 4,250,000. The vote was 1,879,857 "For" versus 23,547 "Against."
  • Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2016, with 2,442,759 votes "For" and zero "Against."

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder vote outcomes.

Investor Verification Checklist

  • Verify the impact of the increased equity pool (from 2.25M to 4.25M shares) on potential future dilution.
  • Confirm the tenure and background of the newly elected Class II directors, John M. Desmarais and Paul Jude Tonna.
  • Review the full 2010 Equity Participation Plan amendment details to understand vesting schedules and eligibility.
  • Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2016, as this 8-K contains no financial data.